Submitted by Anonymous (not verified) on 27 November 2023 - 10:38
Human medicines European public assessment report (EPAR): Tasigna, nilotinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Date of authorisation: 19/11/2007, Revision: 45, Status: Authorised
Source: